Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Swedish Orphan Biovitrum publ AB Maintains FY 2013 Revenue Guidance


Wednesday, 30 Oct 2013 03:00am EDT 

Swedish Orphan Biovitrum publ AB (SOBI) announced that the Company's outlook for the fiscal year 2013 remains unchanged with the total revenues for the full fiscal year 2013 expected to be in the range of SEK 2,000 million to SEK 2,200 million. According to I/B/E/S Estimates analysts on average are expecting SOBI to report revenue of SEK 2,122.53 million for the fiscal year 2013. 

Latest Key Developments in Pharmaceuticals

Company Quote

85.75
-0.25 -0.29%
11 Jul 2014